- Home
- VNO vs IONS Comparison
VNO vs IONS Comparison
Compare VNO & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- IONS
- Stock Information
- Founded
- VNO 1946
- IONS 1989
- Country
- VNO United States
- IONS United States
- Employees
- VNO N/A
- IONS N/A
- Industry
- VNO Real Estate Investment Trusts
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- IONS Health Care
- Exchange
- VNO Nasdaq
- IONS Nasdaq
- Market Cap
- VNO 7.0B
- IONS 6.8B
- IPO Year
- VNO N/A
- IONS 1991
- Fundamental
- Price
- VNO $38.60
- IONS $41.73
- Analyst Decision
- VNO Hold
- IONS Buy
- Analyst Count
- VNO 11
- IONS 16
- Target Price
- VNO $37.91
- IONS $58.25
- AVG Volume (30 Days)
- VNO 1.9M
- IONS 2.0M
- Earning Date
- VNO 08-04-2025
- IONS 07-31-2025
- Dividend Yield
- VNO 1.91%
- IONS N/A
- EPS Growth
- VNO 248.25
- IONS N/A
- EPS
- VNO 0.52
- IONS N/A
- Revenue
- VNO $1,929,890,000.00
- IONS $717,253,000.00
- Revenue This Year
- VNO N/A
- IONS $7.98
- Revenue Next Year
- VNO $4.97
- IONS $16.09
- P/E Ratio
- VNO $73.73
- IONS N/A
- Revenue Growth
- VNO 2.98
- IONS N/A
- 52 Week Low
- VNO $26.19
- IONS $23.95
- 52 Week High
- VNO $46.63
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- VNO 50.76
- IONS 63.92
- Support Level
- VNO $37.45
- IONS $41.22
- Resistance Level
- VNO $38.88
- IONS $42.95
- Average True Range (ATR)
- VNO 1.22
- IONS 1.36
- MACD
- VNO -0.05
- IONS 0.05
- Stochastic Oscillator
- VNO 59.66
- IONS 70.80
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.